vs
爱齐科技（ALGN）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
爱齐科技的季度营收约是Pediatrix Medical Group, Inc.的2.1倍（$1.0B vs $493.8M）。爱齐科技净利率更高（13.0% vs 6.8%，领先6.1%）。爱齐科技同比增速更快（5.3% vs -1.7%）。过去两年爱齐科技的营收复合增速更高（2.5% vs -0.1%）
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
ALGN vs MD — 直观对比
营收规模更大
ALGN
是对方的2.1倍
$493.8M
营收增速更快
ALGN
高出7.0%
-1.7%
净利率更高
ALGN
高出6.1%
6.8%
两年增速更快
ALGN
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $493.8M |
| 净利润 | $135.8M | $33.7M |
| 毛利率 | 65.3% | — |
| 营业利润率 | 14.8% | 9.9% |
| 净利率 | 13.0% | 6.8% |
| 营收同比 | 5.3% | -1.7% |
| 净利润同比 | 30.8% | 10.5% |
| 每股收益（稀释后） | $1.88 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALGNMD
| Q4 25 | $1.0B | $493.8M | ||
| Q3 25 | $995.7M | $492.9M | ||
| Q2 25 | $1.0B | $468.8M | ||
| Q1 25 | $979.3M | $458.4M | ||
| Q4 24 | $995.2M | $502.4M | ||
| Q3 24 | $977.9M | $511.2M | ||
| Q2 24 | $1.0B | $504.3M | ||
| Q1 24 | $997.4M | $495.1M |
净利润ALGNMD
| Q4 25 | $135.8M | $33.7M | ||
| Q3 25 | $56.8M | $71.7M | ||
| Q2 25 | $124.6M | $39.3M | ||
| Q1 25 | $93.2M | $20.7M | ||
| Q4 24 | $103.8M | $30.5M | ||
| Q3 24 | $116.0M | $19.4M | ||
| Q2 24 | $96.6M | $-153.0M | ||
| Q1 24 | $105.0M | $4.0M |
毛利率ALGNMD
| Q4 25 | 65.3% | — | ||
| Q3 25 | 64.2% | — | ||
| Q2 25 | 69.9% | — | ||
| Q1 25 | 69.5% | — | ||
| Q4 24 | 70.0% | — | ||
| Q3 24 | 69.7% | — | ||
| Q2 24 | 70.3% | — | ||
| Q1 24 | 70.0% | — |
营业利润率ALGNMD
| Q4 25 | 14.8% | 9.9% | ||
| Q3 25 | 9.7% | 13.8% | ||
| Q2 25 | 16.1% | 12.8% | ||
| Q1 25 | 13.4% | 7.0% | ||
| Q4 24 | 14.5% | 7.8% | ||
| Q3 24 | 16.6% | 6.6% | ||
| Q2 24 | 14.3% | -31.3% | ||
| Q1 24 | 15.5% | 3.2% |
净利率ALGNMD
| Q4 25 | 13.0% | 6.8% | ||
| Q3 25 | 5.7% | 14.5% | ||
| Q2 25 | 12.3% | 8.4% | ||
| Q1 25 | 9.5% | 4.5% | ||
| Q4 24 | 10.4% | 6.1% | ||
| Q3 24 | 11.9% | 3.8% | ||
| Q2 24 | 9.4% | -30.3% | ||
| Q1 24 | 10.5% | 0.8% |
每股收益（稀释后）ALGNMD
| Q4 25 | $1.88 | $0.40 | ||
| Q3 25 | $0.78 | $0.84 | ||
| Q2 25 | $1.72 | $0.46 | ||
| Q1 25 | $1.27 | $0.24 | ||
| Q4 24 | $1.40 | $0.37 | ||
| Q3 24 | $1.55 | $0.23 | ||
| Q2 24 | $1.28 | $-1.84 | ||
| Q1 24 | $1.39 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $375.2M |
| 总债务越低越好 | — | $570.5M |
| 股东权益账面价值 | $4.0B | $865.9M |
| 总资产 | $6.2B | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资ALGNMD
| Q4 25 | $1.1B | $375.2M | ||
| Q3 25 | $1.0B | $340.1M | ||
| Q2 25 | $901.2M | $224.7M | ||
| Q1 25 | $873.0M | $99.0M | ||
| Q4 24 | $1.0B | $229.9M | ||
| Q3 24 | $1.0B | $103.8M | ||
| Q2 24 | $761.4M | $19.4M | ||
| Q1 24 | $865.8M | $8.0M |
总债务ALGNMD
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALGNMD
| Q4 25 | $4.0B | $865.9M | ||
| Q3 25 | $4.0B | $890.7M | ||
| Q2 25 | $3.9B | $833.8M | ||
| Q1 25 | $3.8B | $789.2M | ||
| Q4 24 | $3.9B | $764.9M | ||
| Q3 24 | $3.9B | $732.5M | ||
| Q2 24 | $3.8B | $706.5M | ||
| Q1 24 | $3.8B | $856.2M |
总资产ALGNMD
| Q4 25 | $6.2B | $2.2B | ||
| Q3 25 | $6.2B | $2.2B | ||
| Q2 25 | $6.2B | $2.1B | ||
| Q1 25 | $6.1B | $2.0B | ||
| Q4 24 | $6.2B | $2.2B | ||
| Q3 24 | $6.4B | $2.1B | ||
| Q2 24 | $6.2B | $2.0B | ||
| Q1 24 | $6.2B | $2.2B |
负债/权益比ALGNMD
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $223.2M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $187.3M | — |
| 自由现金流率自由现金流/营收 | 17.9% | — |
| 资本支出强度资本支出/营收 | 3.4% | — |
| 现金转化率经营现金流/净利润 | 1.64× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $490.8M | — |
8季度趋势，按日历期对齐
经营现金流ALGNMD
| Q4 25 | $223.2M | $114.1M | ||
| Q3 25 | $188.7M | $137.3M | ||
| Q2 25 | $128.7M | $137.2M | ||
| Q1 25 | $52.7M | $-117.5M | ||
| Q4 24 | $286.1M | $133.0M | ||
| Q3 24 | $263.7M | $91.8M | ||
| Q2 24 | $159.8M | $107.0M | ||
| Q1 24 | $28.7M | $-125.2M |
自由现金流ALGNMD
| Q4 25 | $187.3M | — | ||
| Q3 25 | $169.0M | — | ||
| Q2 25 | $107.2M | — | ||
| Q1 25 | $27.4M | — | ||
| Q4 24 | $263.1M | — | ||
| Q3 24 | $233.9M | — | ||
| Q2 24 | $106.4M | — | ||
| Q1 24 | $19.3M | — |
自由现金流率ALGNMD
| Q4 25 | 17.9% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 10.6% | — | ||
| Q1 25 | 2.8% | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 10.3% | — | ||
| Q1 24 | 1.9% | — |
资本支出强度ALGNMD
| Q4 25 | 3.4% | — | ||
| Q3 25 | 2.0% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | 0.9% | — |
现金转化率ALGNMD
| Q4 25 | 1.64× | 3.39× | ||
| Q3 25 | 3.33× | 1.91× | ||
| Q2 25 | 1.03× | 3.49× | ||
| Q1 25 | 0.57× | -5.66× | ||
| Q4 24 | 2.76× | 4.36× | ||
| Q3 24 | 2.27× | 4.72× | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 0.27× | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALGN
暂无分部数据
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
